ReviewEuropean journal of pharmacology2009
Mathematical modeling as a tool for planning anticancer therapy.
Review in European journal of pharmacology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 120 citations in OpenAlex.
- Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer.Breast cancer research : BCR · 2016Trial
- Cell Population Dynamics Informed by Cell-Cycle Regulation: A Deterministic Modeling Toolkit.Computational and structural biotechnology journal · 2026Review
- Analysing the Structural Identifiability and Observability of Mechanistic Models of Tumour Growth.Bioengineering (Basel, Switzerland) · 2025Article
- Fast model calibration for predicting the response of breast cancer to chemotherapy using proper orthogonal decomposition.Journal of computational science · 2024Article
- Combination treatment optimization using a pan-cancer pathway model.PLoS computational biology · 2021Article
- Review
- Predicting Time to Relapse in Acute Myeloid Leukemia through Stochastic Modeling of Minimal Residual Disease Based on Clonality Data.Computational and systems oncology · 2021Article
- Personalized Immunotherapy Treatment Strategies for a Dynamical System of Chronic Myelogenous Leukemia.Cancers · 2021Article
- Modelling of combination therapy using implantable anticancer drug delivery with thermal ablation in solid tumor.Scientific reports · 2020Article
- Bayesian Information-Theoretic Calibration of Radiotherapy Sensitivity Parameters for Informing Effective Scanning Protocols in Cancer.Journal of clinical medicine · 2020Article
- Mathematical model predicts response to chemotherapy in advanced non-resectable non-small cell lung cancer patients treated with platinum-based doublet.PLoS computational biology · 2020Article
- Modeling iontophoretic drug delivery in a microfluidic device.Lab on a chip · 2020Article
- Model-based optimization of combination protocols for irradiation-insensitive cancers.Scientific reports · 2020Article
- Limiting tumor seeding as a therapeutic approach for metastatic disease.Pharmacology & therapeutics · 2019Review
- Array of translational systems pharmacodynamic models of anti-cancer drugs.Journal of pharmacokinetics and pharmacodynamics · 2016Review
- Steering Evolution with Sequential Therapy to Prevent the Emergence of Bacterial Antibiotic Resistance.PLoS computational biology · 2015Article
- Dosage and Dose Schedule Screening of Drug Combinations in Agent-Based Models Reveals Hidden Synergies.Frontiers in physiology · 2015Article
- Treatment Analysis in a Cancer Stem Cell Context Using a Tumor Growth Model Based on Cellular Automata.PloS one · 2015Article
- Classical mathematical models for description and prediction of experimental tumor growth.PLoS computational biology · 2014Article
- Current advances in mathematical modeling of anti-cancer drug penetration into tumor tissues.Frontiers in oncology · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
We review a large volume of literature concerning mathematical models of cancer therapy, oriented towards optimization of treatment protocols. The review, although partly idiosyncratic, covers such major areas of therapy optimization as phase-specific chemotherapy, antiangiogenic therapy and therapy under drug resistance. We start from early cell cycle progression models, very simple but admitting explicit mathematical solutions, based on methods of control theory. We continue with more complex models involving evolution of drug resistance and pharmacokinetic and pharmacodynamic effects. Then, we consider two more recent areas: angiogenesis of tumors and molecular signaling within and among cells. We discuss biological background and mathematical techniques of this field, which has a large although only partly realized potential for contributing to cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.